Cellular immunotherapy for cancer: Current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines: Part I

Clinical Oncology

Volumn 16, Issue 5, 2004, Pages 356-365

  Quatan, N ^a   Spicer, J ^b   Plunkett, T ^b   Pandha, H ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant radiotherapy; Adnexal involvement; Endometrial cancer; Lymph node involvement; Peritoneal cytology; Serosal involvement; Treatment results

Indexed keywords

BCG VACCINE; CALRETICULIN; CANCER VACCINE; CYTOKINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; FREUND ADJUVANT; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 90; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; KEYHOLE LIMPET HEMOCYANIN; MELAN A; MELANOMA ANTIGEN 1; MONOPHENOL MONOOXYGENASE; ONCOPROTEIN; PLASMID DNA; PROTEIN P53; QS 21; SAPONIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VACCINIA ONCOLYSATE; WHOLE CELL VACCINE;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; GENE TARGETING; GENE TRANSFER; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL; VACCINE PRODUCTION;

EID: 3242746008     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2004.03.013     Document Type: Article

References (104)

1. Dunn G.P. Bruce A.T. Ikeda H. Old L.J. Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 2002 991-998
2. Boon T. van Baren N. Immunosurveillance against cancer and immunotherapy: synergy or antagonism? N Engl J Med 348 2003 252-254
3. Zinkernagel R.M. Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system Nature 248 1974 701-702
4. Bjorkman P.J. Saper M.A. Samraoui B. Bennett W.S. Strominger J.L. Wiley D.C. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens Nature 329 1987 512-518
5. Brown J.H. Jardetzky T.S. Gorga J.C. et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 Nature 364 1993 33-39
6. Garcia K.C. Degano M. Stanfield R.L. et al. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex Science 274 1996 209-219
7. Madden D.R. The three-dimensional structure of peptide-MHC complexes Annu Rev Immunol 13 1995 587-622
8. Huang A.Y. Golumbek P. Ahmadzadeh M. Jaffee E. Pardoll D. Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens Science 264 1994 961-965
9. Lizee G. Basha G. Tiong J. et al. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain Nat Immunol 4 2003 1065-1073
10. Valitutti S. Muller S. Cella M. Padovan E. Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes Nature 375 1995 148-151
11. Chambers C.A. Krummel M.F. Boitel B. et al. The role of CTLA-4 in the regulation and initiation of T-cell responses Immunol Rev 153 1996 27-43
12. Kaech S.M. Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells Nat Immunol 2 2001 415-422
13. van Stipdonk M.J. Lemmens E.E. Schoenberger S.P. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation Nat Immunol 2 2001 423-429
14. Townsend S.E. Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells Science 259 1993 368-370
15. Huang A.Y.C. Bruce A.T. Pardoll D.M. Levitsky H.I. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter Immunity 4 1996 349-355
16. Toes R.E. Kast W.M. Blom R.J. Bakker S.C. Offringa R. Melief C.J. Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts Int J Cancer 66 1996 686-691
17. Heath W.R. Carbone F.R. Cytotoxic T lymphocyte activation by cross-priming Curr Opin Immunol 11 1999 314-318
18. Heath W.R. Carbone F.R. Cross-presentation in viral immunity and self-tolerance Nat Rev Immunol 1 2001 126-134
19. Butcher E.C. Picker L.J. Lymphocyte homing and homeostasis Science 272 1996 60-66
20. Banchereau J. Briere F. Caux C. et al. Immunobiology of dendritic cells Annu Rev Immunol 18 2000 767-811
21. Ludewig B. Oehen S. Barchiesi F. Schwendener R.A. Hengartner H. Zinkernagel R.M. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells J Immunol 163 1999 1839-1844
22. Hrouda D. Baban B. Dunsmuir W.D. Kirby R.S. Dalgleish A.G. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172) Br J Urol 82 1998 568-573
23. Matzinger P. Tolerance, danger, and the extended family Annu Rev Immunol 12 1994 991-1045
24. Gallucci S. Matzinger P. Danger signals: SOS to the immune system Curr Opin Immunol 13 2001 114-119
25. McLellan A.D. Brocker E.B. Kampgen E. Dendritic cell activation by danger and antigen-specific T-cell signalling Exp Dermatol 9 2000 313-322
26. Janeway C.A. Jr. The immune system evolved to discriminate infectious nonself from noninfectious self Immunol Today 13 1992 11-16
27. Matzinger P. An innate sense of danger Semin Immunol 10 1998 399-415
28. Fuchs E.J. Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 8 1996 271-280
29. Ridge J.P. Fuchs E.J. Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells Science 271 1996 1723-1726
30. Bennett S.R. Carbone F.R. Karamalis F. Flavell R.A. Miller J.F. Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling Nature 393 1998 478-480
31. Boon T. Cerottini J.-C. van den Eynde B. van der Bruggen P. van Pel A. Tumor antigens recognised by lymphocytes Annu Rev Immunol 12 1994 337-365
32. van den Eynde B. Peeters O. De Backer O. Gaugler B. Lucas S. Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma J Exp Med 182 1995 689-698
33. Wolfel T. Hauer M. Klehmann E. et al. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL) Int J Cancer 55 1993 237-244
34. Prevost-Blondel A. Lengagne R. Letourneur F. Pannetier C. Gomard E. Guillet J.G. In vivo longitudinal analysis of a dominant TCR repertoire selected in human response to influenza virus Virology 233 1997 93-104
35. Gilboa E. The makings of a tumor rejection antigen Immunity 11 1999 263-270
36. Renkvist N. Castelli C. Robbins P.F. Parmiani G. A listing of human tumor antigens recognized by T cells Cancer Immunol Immunother 50 2001 3-15
37. Sahin U. Tureci O. Schmitt H. et al. Human neoplasms elicit multiple specific immune responses in the autologous host In: Proc Natl Acad Sci U S A 92 1995 11810-11813
38. van der Bruggen P. Traversari C. Chomez P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 1991 1643-1647
39. Chen Y.T. Cancer vaccine: identification of human tumor antigens by SEREX Cancer J 6 suppl 3 2000 208-217
40. Tureci O. Sahin U. Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications Mol Med Today 3 1997 342-349
41. Minenkova O. Pucci A. Pavoni E. et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients Int J Cancer 106 2003 534-544
42. Kim N.W. Piatyszek M.A. Prowse K.R. et al. Specific association of human telomerase activity with immortal cells and cancer Science 266 1994 2011-2015
43. Shay J.W. Bacchetti S. A survey of telomerase activity in human cancer Eur J Cancer 33 1997 787-791
44. Kolquist K.A. Ellisen L.W. Counter C.M. et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues Nat Genet 19 1998 182-186
45. Vonderheide R.H. Hahn W.C. Schultze J.L. Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes Immunity 10 1999 673-679
46. Minev B. Hipp J. Firat H. Schmidt J.D. Langlade-Demoyen P. Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans In: Proc Natl Acad Sci U S A 97 2000 4796-4801
47. Chen J.L. Dunbar P.R. Gileadi U. et al . Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL J Immunol 165 2000 948-955
48. Romero P. Dutoit V. Rubio-Godoy V. et al. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences Clin Cancer Res 7 suppl 3 2001 766-772
49. Ramon G. Chassigneux A. Richou R. Gerbeaux C. [Sodium nucleate, immunity adjuvant and stimulant]. C R Hebd Seances Acad Sci 1952;235:111-114.
50. Singh M. O'Hagan D. Advances in vaccine adjuvants Nat Biotechnol 17 1999 1075-1081
51. Haley J.L. Young D.G. Alexandroff A. James K. Jackson A.M. Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha Immunology 96 1999 114-121
52. Alexandroff A.B. Jackson A.M. O'Donnell M.A. James K. BCG immunotherapy of bladder cancer: 20 years on Lancet 353 1999 1689-1694
53. Duda R.B. Yang H. Dooley D.D. Abu-Jawdeh G. Recombinant BCG therapy suppresses melanoma tumor growth Ann Surg Oncol 2 1995 542-549
54. Molto L.M. Carballido J. Jurincic C. et al. Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder Eur Urol 19 1991 74-78
55. Thurnher M. Klocker H. Papesh C. et al. Dendritic cells for the immunotherapy of renal cell carcinoma Urol Int 59 1997 1-5
56. Shimizu K. Thomas E.K. Giedlin M. Mule J.J. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein Cancer Res 61 2001 2618-2624
57. Kensil C.R. Wu J.Y. Anderson C.A. Wheeler D.A. Amsden J. QS-21 and QS-7: purified saponin adjuvants Dev Biol Stand 92 1998 41-47
58. Jakob T. Walker P.S. Krieg A.M. Udey M.C. Vogel J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA J Immunol 161 1998 3042-3049
59. Davis H.L. Weeratna R. Waldschmidt T.J. et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen J Immunol 160 1998 870-876
60. Berzofsky J.A. Mechanisms of T cell recognition with application to vaccine design Mol Immunol 28 1991 217-223
61. Blum J.S. Ma C. Kovats S. Antigen-presenting cells and the selection of immunodominant epitopes Crit Rev Immunol 17 1997 411-417
62. Mayordomo J.I. Loftus D.J. Sakamoto H. et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines J Exp Med 183 1996 1357-1365
63. Marchand M. van Baren N. Weynants P. et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1 Int J Cancer 80 1999 219-230
64. Jensen F.C. Savary J.R. Diveley J.P. Chang J.C. Adjuvant activity of incomplete Freund's adjuvant Adv Drug Deliv Rev 32 1998 173-186
65. Slingluff Jr. C.L. Yamshchikov G. Neese P. et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes Clin Cancer Res 7 2001 3012-3024
66. Jager E. Gnjatic S. Nagata Y. et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers Proc Natl Acad Sci U S A 97 2000 12198-12203
67. Lee P. Wang F. Kuniyoshi J. et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma J Clin Oncol 19 2001 3836-3847
68. Murphy G. Tjoa B. Ragde H. Kenny G. Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen Prostate 29 1996 371-380
69. Nestle F.O. Alijagic S. Gilliet M. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments] Nat Med 4 1998 328-332
70. Disis M.L. Cheever M.A. Oncogenic proteins as tumor antigens Curr Opin Immunol 8 1996 637-642
71. Renard V. Sonderbye L. Ebbehoj K. et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice J Immunol 171 2003 1588-1595
72. Ioannides C.G. Freedman R.S. Patenia R. Bowen J.M. Ward N.E. O'Brian C.A. Immunological effects of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells In Vivo 5 1991 1-6
73. Bai L. Koopmann J. Fiola C. Fournier P. Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients Int J Oncol 21 2002 685-694
74. Ulmer J.B. Donnelly J.J. Parker S.E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein Science 259 1993 1745-1749
75. Krieg A.M. Yi A.K. Schorr J. Davis H.L. The role of CpG dinucleotides in DNA vaccines Trends Microbiol 6 1998 23-27
76. Condon C. Watkins S.C. Celluzzi C.M. Thompson K. Falo L.D. DNA-based immunization by in vivo transfection of dendritic cells Nature Med 2 1996 1122-1128
77. Stevenson F.K. Zhu D. King C.A. Ashworth L.J. Kumar S. Hawkins R.E. Idiotypic DNA vaccines against B-cell lymphoma Immunol Rev 145 1995 211-228
78. Nabel G. Nabel E. Yang Z.-Y. et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans Proc Natl Acad Sci U S A 90 1993 11307-11311
79. Sun W.H. Burkholder J.K. Sun J. et al. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice Proc Natl Acad Sci U S A 92 1995 2889-2893
80. Hartl F.U. Molecular chaperones in cellular protein folding Nature 381 1996 571-579
81. Srivastava P.K. Udono H. Blachere N.E. Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming Immunogenetics 39 1994 93-98
82. Basu S. Binder R.J. Ramalingam T. Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin Immunity 14 2001 303-313
83. Feng H. Zeng Y. Graner M.W. Likhacheva A. Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity Blood 101 2003 245-252
84. Graner M.W. Zeng Y. Feng H. Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers Cancer Immunol Immunother 52 2003 226-234
85. Belli F. Testori A. Rivoltini L. et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings J Clin Oncol 20 2002 4169-4180
86. Ward S. Casey D. Labarthe M.C. et al. Immunotherapeutic potential of whole tumour cells Cancer Immunol Immunother 51 2002 351-357
87. Fabre J.W. The allogeneic response and tumor immunity Nat Med 7 2001 649-652
88. Simons J.W. Mikhak B. Chang J.F. et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer Cancer Res 59 1999 5160-5168
89. Hull G.W. McCurdy M.A. Nasu Y. et al. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines [in process citation] Clin Cancer Res 6 2000 4101-4109
90. Banchereau J. Steinman R.M. Dendritic cells and the control of immunity Nature 392 1998 245-252
91. Holtl L. Zelle-Rieser C. Gander H. et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells Clin Cancer Res 8 2002 3369-3376
92. Celluzzi C.M. Mayordomo J.I. Storkus W.J. Lotze M.T. Falo L.D. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity J Exp Med 183 1996 283-287
93. Panelli M.C. Wunderlich J. Jeffries J. et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100 J Immunother 23 2000 487-498
94. Heiser A. Coleman D. Dannull J. et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors J Clin Invest 109 2002 409-417
95. Wan Y. Bramson J. Carter R. Graham F. Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination Hum Gene Ther 8 1997 1355-1363
96. Gong J. Chen D. Kashiwaba M. Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells Nat Med 3 1997 558-561
97. Hsu F.J. Benike C. Fagnoni F. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med 2 1996 52-58
98. Murphy G. Tjoa B. Ragde H. Kenny G. Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen Prostate 29 1998 371-380
99. Santin A.D. Hermonat P.L. Hiserodt J.C. et al. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer Int J Radiat Oncol Biol Phys 39 1997 737-742
100. Seo A. Ishikawa F. Nakano H. Nakazaki H. Kobayashi K. Kakiuchi T. Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation Immunology 96 1999 642-648
101. Hareyama M. Imai K. Kubo K. et al. Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells Cancer 67 1991 2269-2274
102. Morel A. Fernandez N. de La Coste A. et al. Gamma-ray irradiation induces B7.1 costimulatory molecule neoexpression in various murine tumor cells Cancer Immunol Immunother 46 1998 277-282
103. Lumniczky K. Desaknai S. Mangel L. et al. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model Cancer Gene Ther 9 2002 44-52
104. Nishisaka N. Maini A. Kinoshita Y. et al. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines J Immunother 22 1999 308-314